Interactive Web Platform for EmPOWERment in Early Multiple Sclerosis

Multiple Sclerosis Clinical Trial

— POWER@MS1  

Official title:

Development and Evaluation of a Web-based Lifestyle Intervention for EmPOWERment in Early Multiple Sclerosis (POWER@MS1) - a Randomized Controlled Trial and Mixed-methods Process Evaluation

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03968172
• Other study ID #: POWER@MS1
• Status: Completed
• Phase: N/A
• Start date: July 1, 2019
• Est. completion date: April 5, 2023

Study information

• Verified date: September 2023
• Source: Universitätsklinikum Hamburg-Eppendorf
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This randomized controlled trial with an accompanying process evaluation investigates the hypothesis that behavioural and web-based information on immunotherapy decisions, disease management and lifestyle can change patient behaviour resulting in reduced inflammatory disease activity in multiple sclerosis.

Description:

After a multiple sclerosis (MS) diagnosis, uncertainty and psychological stress may have a negative effect on the disease course, while psychological counselling may reduce inflammatory activity. Therefore, especially newly diagnosed patients require intensive and individual support to deal with the disease and to initiate lifestyle changes. This is hardly available in standard care. Systematic, evidence-based patient information on the value of lifestyle change is not available either.

POWER@MS1 aims to encourage patients with MS to find the best way of dealing with the disease on the basis of evidence-based patient information (EBPI) and a complex behaviour change intervention. The platform will serve as a disease accompanying empowerment programme. Various modules will be provided to accompany patients with MS (pwMS) at an early stage of the disease. The multicomponent intervention will offer comprehensive support after diagnosis, which includes, firstly, an immunotherapy decision-support programme aligned with principles of shared decision-making (SDM), and, secondly, a behaviour-change intervention promoting disease management and lifestyle habits over a period of one year. Ideally, POWER@MS1 leads to a more targeted immunotherapy start, and consequently to better adherence and optimization of a preventive effective lifestyle.

Primary objective:

To determine if a web-based behavioural intervention on immunotherapy decision making, disease management, and lifestyle can reduce the inflammatory disease activity in MS (a relapse or - as a surrogate for inflammatory disease activity - new T2 lesions on magnetic resonance imaging (MRI)).

Secondary objectives:

The secondary objectives are to determine if the web-based intervention can

• strengthen patient autonomy and empowerment,

• promote informed decisions on immunotherapy,

• improve quality of life,

• reduce anxiety and depression,

• increase physical activity and a healthy diet,

• increase effectiveness of neurologists encounters,

• and save health care costs.

In order to develop and evaluate the intervention, a multiphase mixed-methods study covering the first three phases of the Medical Research Council Framework for complex interventions will be conducted. After development, the intervention programme will be pretested and piloted with experts and persons with MS (pwMS). The intervention will be evaluated in a randomized controlled trial (RCT) with 328 patients with early MS (< 12 months), who have at least two MS-typical lesions. Study participants will be recruited in 19 MS centres across Germany and randomised to an intervention group with access to an evidence-based information platform or to a control group with optimised standard care based on material of the German Multiple Sclerosis Society (DMSG). The primary endpoint will be reached if new T2 lesions or relapses occur. Furthermore, a mixed methods process evaluation and a health economic evaluation will be carried out.

Recalculated sample size: Based on a blinded data export of August 16th, 2021, with data on event rates (primary endpoint: new T2 lesion or new relapse) of 135 included patients at that time, a blinded sample size recalculation was performed. The sample size recalculation resulted in a lower number of necessary cases due to high event rates (51 primary endpoint events at that time). The calculation of event rates and an assumed dropout rate of 20% resulted in a case number of 216 patients that have to be randomized (108 per group) instead of 328.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 234
• Est. completion date: April 5, 2023
• Est. primary completion date: April 5, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• signed informed consent

• clinically isolated syndrome (CIS), suspected or confirmed MS for less than 12 months

• at least two MS-typical lesions on T2-weighted images on MRI scans

• MS typical cerebrospinal fluid (CSF) finding with detection of oligoclonal bands

• access to the internet and ability to use websites

Exclusion Criteria:

• corticosteroid therapy within 4 weeks prior to study inclusion

• substantial psychiatric disorder (based on clinical impression)

• severe cognitive deficit affecting information uptake (based on clinical impression)

• pregnancy

• claustrophobia

Related Conditions & MeSH terms

• Multiple Sclerosis
• Sclerosis

Intervention

Behavioral:
• EBBC programme
Web-based behavioural lifestyle intervention that provides patients with coordinated information based on their existing health beliefs, interests, etc. In the programme, techniques and exercises will be taught in sequentially active interactive learning units ("simulated dialogues") and followed-up with email and SMS reminders in the second study year. The following topics will be focused on: Diagnosis and disease progression Support in disease processing Techniques for coping with stress and depressive symptoms as well as developing positive emotions Optimisation of dietary behaviour Optimisation of physical activity behaviour Sleep hygiene and methods for dealing with insomnia. The programme will accompany each patient with information material and e-mail reminders over a period of 12 months with initial 2-3 weekly tasks, later only weekly reminders and inputs every 2 weeks. All in all, the intervention programme will consist of 16 modules.
• Control group programme
Web-based information platform with optimized standard care compiled from information material of the German Multiple Sclerosis Society (DMSG). Information will be provided in sequentially activated modules over a period of 12 months, covering the following topics: Disease progression Invisible symptoms of multiple sclerosis Symptomatic therapy Immunotherapy decision support Coping strategies Autonomy Fatigue Quality of life Physical activity Nutritional behaviour In addition, a reminder system with neutral e-mail reminders will be used to promote the use of the programme.

Locations

Country	Name	City	State
Germany	Universitätsklinikum Hamburg-Eppendorf	Hamburg

Sponsors (8)

Lead Sponsor	Collaborator
Universitätsklinikum Hamburg-Eppendorf	BKK Dachverband e.V., Charite University, Berlin, Germany, Deutsche Multiple Sklerose Gesellschaft (DMSG), Gaia AG, Heinrich-Heine University, Duesseldorf, University Medical Center Goettingen, University of Cologne

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Occurrence of new lesions on T2-weighted images on MRI scans	As a surrogate for inflammatory disease activity, new T2 lesions will be assessed in MRI.; MRI protocol: Localizer, 3D FLAIR sagittal e.g. 3x3mmm, 3D image T1w native sagittal, 1-3mm, PD/T2w axial 3mm, protocol duration approx. 20 min.	Change in the number of lesions on T2-weighted images from immediately after patient inclusion (month 0), to month 3, 6, 12, 18 (follow-up) and 24 (follow-up) after patient inclusion
Primary	Time to a second relapse	Duration of complaints/impairment, relapse symptoms (worsened or newly occurred), degree of impairment due to the relapse and degree of certainty with regard to the classification of the worsening as a relapse.	Change in relapse status from baseline (no endpoint), to month 1, 3, 6, 12, 18 (follow-up), and 24 (follow-up) after patient inclusion
Secondary	Risk Knowledge (RiKno10)	To assess risk knowledge, RiKno 2.0 was adapted to a 10-item version (RiKno10).	Month 3 after patient inclusion
Secondary	Control Preference Scale (CPS)	As a surrogate of decision quality, preferred and realized role preference based on the Control Preference Scale (CPS) will be assessed. The scores for preferred and realized roles are grouped into active, collaborative or passive.	Month 12 after patient inclusion, as well as after reaching the primary endpoint
Secondary	Immunotherapy Decision Satisfaction Questionnaire	As a surrogate of decision quality, satisfaction with the immunotherapy decision will be assessed.	After reaching the primary endpoint
Secondary	Immunotherapy Status Questionnaire	It will be assessed whether an immunotherapy was newly started, aborted or changed.	Baseline (no endpoint), month 1, 3, 6, 12, 18 (follow-up), 24 (follow-up) after patient inclusion
Secondary	Patient Activation Measure (PAM)	Assessment of patient activation development (i.e. expressed in the confidence and knowledge to take action, as well as actually taking health-related action).	Baseline and month 12 after patient inclusion
Secondary	Coping self-efficacy (CSE) scale	Based on the coping self-efficacy (CSE) scale, selected and adapted items will be used to measure perceived self-efficacy for emotion-focused coping behaviours. In this study, response options are ranging from 0 (completely disagree), representing a low coping self-efficacy value, to 3 (fully agree), representing a high coping self-efficacy value.	Baseline and month 12 after patient inclusion
Secondary	Changes in Perceived Empowerment Questionnaire	Changes in perceived empowerment will be measured based on selected and adapted items of a 3-point scale empowerment questionnaire measuring changes in patients' feelings of empowerment and/or control over their health problem.	Month 12 after patient inclusion
Secondary	Credibility/Expectancy Questionnaire	Selected items measuring treatment expectancy and credibility.	4 weeks after patient inclusion (month 1)
Secondary	Readiness to Change (stage assessment) based on the Health Action Process Approach (HAPA)	Readiness to change will be assessed based on the Health Action Process Approach (HAPA) in order to determine the interventions impact on willingness to change lifestyle activities, such as physical activity and nutritional behaviour.	Baseline, month 3 and 12 after patient inclusion
Secondary	Impairment in the Expanded Disability Status Scale (EDSS)	MS impairment measurement with a score ranging from 0.0 (normal neurological exam) to 10.0 (death due to MS).	Baseline and month 12 after patient inclusion
Secondary	Hamburg Quality of life in MS Scale (HAQUAMS)	Assessment of MS-specific quality of life based on 8 subscales (consisting of 38 individual items) and 4 additional questions. For all subscales, averaged subscores are calculated from the values of the respective items (ranging from 1 to 5), with high scores standing for low quality of life and low scores standing for high quality of life.	Baseline and month 12 after patient inclusion
Secondary	EQ-5D	Assessment of health-related quality of life.	Baseline, month 6, 12, 18 (follow-up) and 24 (follow-up) after patient inclusion
Secondary	Hospital anxiety and distress scale (HADS)	Assessment of depression and anxiety based on 14 items on 2 scales (7 on the subscale "anxiety" and 7 on the subscale "depression"), ranging from 0 (low anxiety/depression level) to 3 (high anxiety/depression level) per item, resulting in a range of 0 to 21 per scale or 0 to 42 for the total HADS value.	Baseline and month 12 after patient inclusion
Secondary	Godin Leisure-Time Exercise Questionnaire (GLTEQ)	Amount of mild, moderate and strenuous exercise in leisure time.	Baseline and month 12 after patient inclusion
Secondary	Physical Activity, Exercise, and Sport Questionnaire (Bewegungs- und Sportaktivität Fragebogen (BSA-F))	Assessment of physical activity, including occupational activity, leisure time activity and sports.	Baseline and month 12 after patient inclusion
Secondary	Questionnaire of Healthy Diet (QHOD2), adapted version of the Mediterranean Diet Screener (aMDS)	Frequency of intake of characteristic food groups (e.g. vegetables, fish, and olive oil) in the last seven days and is an indicator of the degree of adherence to an adapted Mediterranean dietary pattern.	Baseline, month 3 and 12 after patient inclusion
Secondary	24-h dietary recall myfood24	Aggregated nutrient intake data (e.g. omega-3-fatty acids).	Baseline and month 12 after patient inclusion, in each case three times within two to three weeks (two weekdays and one weekend day)
Secondary	Health Economic Evaluation	Assessment of all direct costs associated with the intervention as well as costs resulting from the consumption of health-related goods and services as well as indirect costs due to productivity losses.	Baseline, month 6, 12, 18 (follow-up) and 24 (follow-up) after patient inclusion